STOCK TITAN

Acrivon Therapeutics, Inc. - ACRV STOCK NEWS

Welcome to our dedicated page for Acrivon Therapeutics news (Ticker: ACRV), a resource for investors and traders seeking the latest updates and insights on Acrivon Therapeutics stock.

Acrivon Therapeutics, Inc. (Nasdaq: ACRV) is a clinical-stage biopharmaceutical company dedicated to developing precision oncology medicines. The company specializes in using its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to match patients with the oncology medicines most likely to work for them. This groundbreaking approach integrates drug-regulated global proteomics with intact tissue digital imaging to create drug-specific biomarker signatures, known as OncoSignature companion diagnostics, for identifying patient responders.

The company's leading candidate, ACR-368 (prexasertib), is a selective small molecule inhibitor targeting CHK1 and CHK2. This drug is currently in a potentially registrational Phase 2 trial and has received Fast Track designation from the FDA for investigating its use as monotherapy for patients with platinum-resistant ovarian or endometrial cancer. The ACR-368 OncoSignature test, which is pending regulatory approval, has shown promising results in preclinical studies and past third-party Phase 2 trials.

Additionally, Acrivon is advancing ACR-2316, a selective dual WEE1/PKMYT1 inhibitor designed using the AP3 platform. This candidate shows superior single-agent activity in preclinical studies compared to benchmark inhibitors. Acrivon plans to submit an IND for ACR-2316 in Q3 2024, with clinical study initiation expected in Q4 2024.

The company's AP3 platform not only aids in drug selection but also in rational drug design and optimization. It's engineered to measure drug effects on the tumor cell protein network, identifying resistance mechanisms and optimal drug combinations.

Recently, Acrivon has made significant strides, including FDA Breakthrough Device designation for its ACR-368 OncoSignature assay and a successful $130 million private placement financing to further fund its innovative pipeline and platform development. Acrivon's focus remains on leveraging its AP3 platform for the development of precision oncology drugs that address significant unmet medical needs, aiming to improve treatment outcomes for cancer patients worldwide.

For more updates and detailed financial information, visit Acrivon's investor relations page.

Rhea-AI Summary
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) announced that its president and CEO, Peter Blume-Jensen, M.D., Ph.D., will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference. Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3). The webcast will be available on the company's website with a replay option for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.63%
Tags
conferences
-
Rhea-AI Summary
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) appoints Jean-Marie Cuillerot, M.D., as chief medical officer and announces other key personnel updates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
management
-
Rhea-AI Summary
Acrivon Therapeutics, Inc. (ACRV) has announced that the FDA has granted Breakthrough Device designation for the ACR-368 OncoSignature assay, a multiplex immunofluorescence assay for the identification of ovarian cancer patients who may benefit from ACR-368 treatment. The designation reflects FDA’s determination that the device is reasonably expected to provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions. Acrivon has partnered with Akoya Biosciences to co-develop, validate, and commercialize ACR-368 OncoSignature assay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
none
Rhea-AI Summary
Acrivon Therapeutics, Inc. (ACRV) announced the participation of its president and CEO in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference. The company is a clinical stage biopharmaceutical firm developing precision oncology medicines utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.02%
Tags
conferences
-
Rhea-AI Summary
Acrivon Therapeutics, Inc. (ACRV) granted an equity award to one employee, consisting of 57,900 stock options, under its 2023 Inducement Plan. The options will vest over a three-year period, subject to continued employment, as part of a material inducement to employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.02%
Tags
none
-
Rhea-AI Summary
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) reported Q3 2023 financial results and business highlights, emphasizing commitment to precision oncology medicines and the Acrivon Predictive Precision Proteomics (AP3) platform. CEO Peter Blume-Jensen highlighted recent presentations and initial clinical readouts for ACR-368, with more data to be presented in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.19%
Tags
Rhea-AI Summary
Acrivon Therapeutics grants equity awards to two employees under its 2023 Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
none
-
Rhea-AI Summary
Acrivon Therapeutics announces selection of two abstracts for poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
-
Rhea-AI Summary
Acrivon Therapeutics announces internally developed clinical candidate ACR-2316, a dual WEE1 and PKMYT1 inhibitor. IND submission planned by Q4 2024. AP3 platform enables rapid generation and optimized design of ACR-2316. Potential for monotherapy development in tumors predicted to be sensitive to ACR-2316 using OncoSignature patient selection approach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
Rhea-AI Summary
Acrivon Therapeutics to participate in two investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
conferences

FAQ

What is the current stock price of Acrivon Therapeutics (ACRV)?

The current stock price of Acrivon Therapeutics (ACRV) is $6.55 as of November 22, 2024.

What is the market cap of Acrivon Therapeutics (ACRV)?

The market cap of Acrivon Therapeutics (ACRV) is approximately 201.5M.

What does Acrivon Therapeutics specialize in?

Acrivon Therapeutics specializes in developing precision oncology medicines using its proprietary AP3 platform to match patients with the most effective treatments.

What is Acrivon's leading drug candidate?

Acrivon's leading drug candidate is ACR-368 (prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2, currently in Phase 2 trials.

What is the Acrivon Predictive Precision Proteomics (AP3) platform?

The AP3 platform integrates drug-regulated global proteomics with intact tissue digital imaging to create drug-specific biomarker signatures, aiding in patient responder identification.

Has Acrivon received any regulatory designations for its drugs?

Yes, Acrivon's ACR-368 has received Fast Track designation from the FDA for treating platinum-resistant ovarian or endometrial cancer.

What recent achievements has Acrivon announced?

Recent achievements include FDA Breakthrough Device designation for the ACR-368 OncoSignature assay and a $130 million private placement financing.

What is the status of Acrivon's ACR-2316 drug candidate?

ACR-2316, a dual WEE1/PKMYT1 inhibitor, is in preclinical development with an IND submission expected in Q3 2024 and clinical studies beginning in Q4 2024.

How does the AP3 platform contribute to drug development?

The AP3 platform helps in measuring drug effects on the tumor cell protein network, identifying resistance mechanisms, and optimizing drug design and combinations.

What is the significance of the ACR-368 OncoSignature test?

The ACR-368 OncoSignature test identifies patients most likely to respond to ACR-368 monotherapy, aiding in personalized treatment plans.

How well-funded is Acrivon for its ongoing and future projects?

Acrivon is well-funded, with recent financing expected to support operations into the second half of 2026, providing flexibility for extended research and development.

Where can investors find more information about Acrivon?

Investors can find more detailed updates and financial information on Acrivon's investor relations page.

Acrivon Therapeutics, Inc.

Nasdaq:ACRV

ACRV Rankings

ACRV Stock Data

201.45M
18.90M
22.39%
75.98%
3.48%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WATERTOWN